S u m m a r y
Objectives: Intravenous immunoglobulin (IVIG) is applied in the treatment of primary immunodeficiency diseases, autoimmune disorders and inflammatory disorders. The mechanism of antiin flammatory action of highdose IVIG is diverse and dependent on the disease entity. The aim of this paper was to define the efficacy and safety of IVIG treatment of rheumatic diseases in children. Material and methods: We performed a retrospective examina tion of the efficacy of IVIG therapy in pediatric rheumatology. All children were treated in the period 1.01.2009 to 31.12.2013 in the Pediatric Rheumatology Department and Pediatric Department in St. Louis Hospital in Kraków and in the Pediatric Rheumatology De partment, Eleonory Reicher Institute of Rheumatology in Warsaw. During 5 years, 70 patients (27 male -38.57%) received IVIG prepa rations, 16 of them in concordance with registration recommenda tions, the others on the basis of reliable published clinical reports. The mean age of children was 6 years, the mean weight was 23.5 kg, and the mean height was 106 cm. Indications for IVIG therapy were: juvenile idiopathic arthritis (JIA), Kawasaki disease (KD), idiopathic thrombocytopenic purpu ra (ITP), juvenile dermatomyositis (JDM), systemic vasculitis (SV), juvenile lupus erythematosus diseminatus (JLED), scleroderma (SCLE). Statistical analysis was performed using Statistica soft ware version 2.0. Results: All patients experienced a beneficial effect of IVIG adju vant therapy -clinical improvement and normalization of laborato ry tests. There were no adverse effects of this therapy.
Introduction IVIG therapy indications
Intravenous immunoglobulin (IVIG) preparations have been used in medicine since the 1950s. In 1952 Ogden Bruton was the first to administer -and achieved sat isfactory results -subcutaneously IgG preparation to an 8yearold boy with agammaglobulinemia [1] . For succes sive decades IgG preparations have been applied intra muscularly and since the 1980s also intravenously [2] . In 1981 Paul Imbach described a significant growth of the number of platelets in patients with immune thrombo cytopenia, treated with IVIG due to immunodeficiencies. This observation was of key importance for making an at tempt of IVIG therapy in a wide spectrum of autoimmune and inflammatory disorders [3] . Nowadays the US Food and Drug Administration (FDA) discerns two main indi cation groups of IVIG therapy. Immunoglobulins are used in primary and secondary immunodeficiencies associated with chronic lymphocytic leukemia, bone marrow trans plantation, and human immunodeficiency virus (HIV) infection. Some autoimmune and chronic inflammatory diseases represent the second group of indications: idio pathic thrombocytopenic purpura (ITP), KD and chronic inflammatory demyelinating polyneuropathy [2, 4] . Fur thermore, different countries state individual recommen dations for administration of IVIG. In Poland IgG prepa rations may be recommended in the following disorders: GuillainBarré syndrome, severe infections in addition to antibacterial and antiviral medications, to prevent infec tions in lowbirthweight preterm infants [5] . In clinical practice, based on reliable literature data, efficacious IgG therapy is also administered in numerous autoimmune diseases in adults and children. Applying IVIG in pediat ric rheumatic disorders with severe course and poor re sponse to a firstline therapy is of particular importance.
Characteristics of immunoglobulin preparations
Modern immunoglobulin preparations consist of im pure polyclonal IgG with IgA and are derived from serum pools obtained from a plurality of human donors. Thera peutic IVIG is produced according to recommendations established by the World Health Organization. There is a low risk of infectious agent transmission during IVIG transfusion due to rigorous standards of production steps [6] .
Immunoglobulin activity mechanism
Lowdose IgG (200-400 mg/kg every 3-4 weeks) ad ministered to patients with immunodeficiency disorders as replacement therapy has proinflammatory proper ties and prevents recurrent infections [7] . In contrast, immunomodulatory and antiinflammatory activity of highdose IgG (1-2 g/kg given over 2 to 5 days) is used for the treatment of autoimmune diseases [7] . These an tiinflammatory mechanisms are derived and consist of the influence on function of the Fcγ receptor, immuno competent cells, the complement cascade and the cyto kine network [8, 9] .
Adverse effects of immunoglobulin
Adverse events may occur following IVIG therapy, much like every treatment. The frequency of adverse events associated with the use of IVIG ranges from sev eral to a dozen or so percent. They are usually classified as mild and do not require the termination of therapy [10, 11] . Risk factors of adverse effects are: initiation of treatment, delay since the last administration, infection, change of immunoglobulin preparation, rapid infusion rate [12] , kidney failure, diabetes, obesity, and advanced age [13] . Severe reactions, mainly anaphylaxis, usually occur soon after infusion and are very rare. The most common adverse events develop 24-72 hours after the administration, and include fever, weakness, face red dening, headaches, nausea, vomiting, cough and rash. Preventive strategies for adverse events include admin istration of antihistamines, nonsteroidal antiinflamma tory drugs and glucocorticoids (CS) [14] . Children under 5 years of age may be particularly susceptible to exces sive overload fluid volume and in this group the dose should be carefully calculated. Especially in children with KD the risk is high due to the impairment of cardiac function. Subcutaneous IgG preparations cause signifi Conclusions: Autoimmune diseases in children are rare, charac terized by diverse clinical course and still unclear pathogenesis. IVIG therapy can be used in pediatric rheumatology as an efficient medication of basic supplementary treatment. Drawing up uni form standards seems to be crucial for IVIG transfusions in pedi atric rheumatology, when the results of primary treatment prove ineffective.
lizacją wyników badań laboratoryjnych. Nie obserwowano działań niepożądanych tej terapii. Wnioski: Choroby autoimmunizacyjne występują u dzieci rzadko. Charakteryzują się zróżnicowanym klinicznie przebiegiem i nie znaną patogenezą. Terapia IVIG może być zastosowana w leczeniu chorób reumatycznych u dzieci jako skuteczna terapia uzupełnia jąca leczenie podstawowe. Istotne wydaje się opracowanie jedno litych standardów terapii IVIG u dzieci z chorobami autoimmuni zacyjnymi o ciężkim przebiegu, przy braku skuteczności leczenia podstawowego.
cantly fewer adverse events; however, they are used as substitutive therapy in immunodeficiencies [13] .
Aim of the study
The aim of this study was to examine the efficacy and safety of IVIG standard and offlabel therapy in chil dren with rheumatic diseases depending on indications for complementary treatment with immunoglobulin.
Material and methods
We performed a retrospective examination of effi cacy of IVIG therapy in pediatric rheumatology. During 5 years, 70 patients (27 male -38.57%) re ceived IVIG preparations, 16 of them in concordance with registration recommendations, the others on the basis of reliable published clinical reports. The mean age of children was 6 years, the mean weight was 23.5 kg, and the mean height was 106 cm.
The indications for use of immunoglobulin were: ju venile idiopathic arthritis (JIA), Kawasaki disease (KD), id iopathic thrombocytopenic purpura (ITP), juvenile derma tomyositis (JDM), systemic vasculitis (SV), juvenile lupus erythematosus diseminatus (JLED), scleroderma (SCLE).
Statistical analysis was performed using Statistica software version 2.0.
Results
During 5 years IVIG infusions were administered to 70 patients (27 male -38.57%) with autoimmune dis orders of severe course. The mean age of children was 6 years, the mean weight was 23.5 kg, and the mean height was 106 cm. The indications were KD, ITP, JIA, JDM, SV, JLED, and SCLE. The mean/median quantity of infusions was 2.32/1.0 (1.0-15.0). The mean/median combined dose was 2.63/1.74 g/kg (0.65-12.22), while the mean/median dose for a series of infusions was 1.38/1.27 g/kg (0.32-3.25); 40 patients required at least two administrations of IVIG.
The largest group of patients treated with immu noglobulin was children with JIA -30 patients (43%). The mean/median quantity of infusions was 3.1/2.0 (1.0-9.0). The mean/median combined dose was 3.33/ 2.26 g/kg (0.71-7.8), while the mean/median dose for a series of infusions was 1.13/0.97 g/kg (0.7-2.65). IVIG therapy was well tolerated, and no significant sudden or late complications occurred. In most children, the results of treatment were satisfactory. Patients with KD constitut ed the second largest group -14 patients (20%). Charac teristics of all groups are presented in Table I . All patients out of this group received one IVIG infusion. The mean/ median combined dose was 1.76/1.68 g/kg (0.96-3.25).
Kawasaki disease
Kawasaki disease (KD) is a systemic vasculitis of the small and mediumsized arteries. It can affect cor onary vessels leading to aneurysms and sudden cardiac death caused by ischemic heart disease. Efficacy of IVIG preparations in preventing developing coronary artery complications in children with KD is widely discussed and documented in the medical literature [15] [16] [17] [18] [19] . The efficiency of immunoglobulin infusions depends on the time since disease onset -initiating treatment within 10 days of the first symptoms is considered to be opti mal [3] . IgG administration should be repeated in case of a nonsatisfactory response to the first application [20] . According to the FDA, KD is a leading indication for highdose IVIG therapy. The mechanism of IVIG activity in KD is presumably complex and involves: neutraliza tion of bacterial superantigens, infectious agents, au toantibodies, inhibition of proinflammatory cytokine production, influence on function of Fcγ receptor and T cells [18] . During the 5year study 14 children with complete KD were observed. On average the admission day was at 5.75 days of fever duration, the mean CRP value was 65.64 mg/l, OB 73.85 mm/h, and blood plate The use of intravenous immunoglobulin in pediatric rheumatology lets 573.07 thousand/µl. Coronary artery abnormalities peculiar to the acute phase of KD were observed in 9 patients (64%). Patients were, on average, adminis tered highdose immunoglobulin therapy on the ninth day of fever duration. We observed tolerance of IVIG treatment, quick clinical recovery and improvement in laboratory parameters described above in 12 patients and 2 children needed several consecutive doses.
Idiopathic thrombocytopenic purpura
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by bleeding risk because of increased platelet destruction. The most fre quent bleeding manifestations are remittent epistaxis, and menorrhagia. Less common are severe lifethreat ening hemorrhages [19] . IVIG usage is approved by the FDA for ITP. Currently, the firstline treatment for ITP is CS therapy, and immunoglobulin preparations are usu ally administered to patients with significant bleeding risk or as a prevention before surgical interventions [3, 5, 21] . Although ITP was the first autoimmune disease with a solid recommendation for IVIG infusions, the mechanism of this therapy is still unclear. Acceleration of antiplatelet antibodies elimination, modulation of function of the Fc receptor and suppression of proin flammatory cytokine production are implicated [22, 23] . Two hospitalized children suffering from ITP required IVIG therapy due to severe thrombocytopenia and nu merous mucocutaneous bleeding episodes. The course of transfusion was uncomplicated and fast platelet count normalization was obtained.
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is one of the most common autoimmune disorders among children. How ever, the diagnosis of juvenile idiopathic arthritis in volves a heterogeneous group of clinical courses deter mined by onset signs. Diagnosis is based on two criteria: arthritis of at least 6 weeks duration and onset before the 16 th year of life. The pathomechanism of JIA is still unknown. An increase of proinflammatory cytokine concentrations seems to play the most important role [24] . Recommendations of IVIG therapy of arthritis are based on case reports published in the 1990s [19] . IVIG administration is highly advised in patients with severe chronic JIA with a poor response to standard immuno suppressants and biologics [3, 25] . A total of 30 children suffering from JIA of very severe course needed immu noglobulin transfusion, and 20 of them received at least two infusions. The indication for this therapy among all patients was exacerbation of chronic disease -at the time of administration the average amount of leuco cytes was 14.85 thousand/µl, CRP 50.2 mg/l, OB 61.12 mm/h. Six patients with JIA were treated because of macrophage activation syndrome -they showed signs of leukopenia, thrombocytopenia, anemia and liver damage. There were no important complications after IVIG administration.
Juvenile dermatomyositis
Juvenile dermatomyositis (JDM) is the most frequent childhood myopathy. It is characterized by symmetrical proximal muscle weakness and skin rash. Dermato myositis is an autoimmune disease and it is probably caused by excessive activation of dendritic cells [26] and the complement cascade followed by hypercyto kinemia [27] . There is solid clinical evidence indicating the efficacy of IVIG therapy in patients with a severe or atypical disease course if there is no satisfactory effect of combined therapy with methotrexate and glucocorti costeroids. Antiinflammatory action of immunoglobulin creates an opportunity to achieve fast clinical improve ment, and as a result, a decrease in CS doses [19, 20, [26] [27] [28] . In this study 7 patients with serious multiple or gan manifestation of JDM were administered IVIG. The clinical outcome was positive and longterm. No severe adverse events were observed, as with the previous groups of patients.
Systemic vasculitis
Systemic vasculitis (SV) is a wide group of autoim mune diseases characterized by inflammation of blood vessels resulting in coagulation disorders and throm boembolic events. Childhood vasculitis is classified by the size of vessels [29] . The pathomechanism of vessel dysfunction in various types of SV seems to be com plex and heterogeneous [30] . The firstline therapy is usually the use of glucocorticosteroids. IVIG can be helpful in severe cases [3] . Especially children with AN CAassociated SV obtain significant benefits from im munoglobulin therapy [19] . In this study 7 patients with SV received immunoglobulin infusions with expected improvement. They needed continuing therapy in or der to maintain the effect. No significant complications were observed.
Juvenile systemic lupus erythematosus
Juvenile systemic lupus erythematosus (JSLE) is a multisystemic autoimmune disease characterized by diversity of symptoms, unpredictable course and varied types of autoantibodies in the blood. The drugs of choice are CS and immunosuppressants. Neurologic symp toms and thrombocytopenia comprise indications for IVIG therapy. The mechanism of action is similar to that in ITP. Additionally, immunoglobulins reduce formation and deposition of the immune complex [31] . A total of 6 patients were treated with IVIG preparations: 3 of them because of serious thrombocytopenia, 1 with thrombocytopenia and hemolytic anemia, 1 with anti phospholipid syndrome, and 1 with chorea as a neuro logic symptom of JSLE. The therapy was safe and bene ficial. No recurrence of acute thrombocytopenic events or CNS effects were observed during the conventional therapy.
Scleroderma
The essence of SCLE is a chronic inflammation of col lagen resulting in fibrosis of connective tissue, skin and internal organs. There is a disturbance in endothelial function and vascular reactivity due to the abnormal an tibody in the blood. The method of treatment depends on the form (limited or diffused) and the clinical course of scleroderma [32] . Treatment with IVIG is helpful in an early phase of systemic vasculitis. The mechanism of action is the same as in JLED. The immunoglobulin in fusions were administered to 2 children suffering from rapidly progressive SCLE. There was a perfect therapeu tic response and no complications.
Differences in IVIG usage among particular disease entities
The treatment with immunoglobulin in Kawasaki dis ease and idiopathic thrombocytopenic purpura is usually shortterm and is intended to prevent serious complica tions. It is expected to reduce the risk of coronary artery dysfunction leading to myocardial infarction in KD and lifethreatening bleeding in ITP. On the other hand, in JDM, SV, JLED and SCLE of severe chronic course with a poor response to conventional therapy, it is a valuable medication of basic treatment and significant reduce of the threat of complications. In the case of systemic JIA, which is resistant to the standard therapy, IVIG in fusions are used to achieve quick but shortterm clinical improvement and laboratory parameters.
Summary
The decision of IVIG therapy initiation in pediatric rheumatology should be preceded by rigorous analysis of clinical condition, disease phase, response to conven tional drugs, prognosis and recommendations based on solid clinical evidence. It is also very important to consider the potential benefit and risk of immunoglob ulin usage. The patient should be properly prepared for the transfusion and possible adverse events should be monitored. Autoimmune diseases in children are rare, characterized by diverse clinical course and still unclear pathogenesis. There are no precise international treat ment recommendations for these disorders. Beside CS, immunosuppressants and biologics, immunoglobulin is becoming a more and more important treatment option. The FDA approved KD and ITP for IVIG therapy. For all the other childhood rheumatic diseases, immunoglob ulin preparations are used "off label" on the basis of doubleblind randomized trials or case reports. In cas es of severe atypical course with poor response to con ventional medicines, IVIGs are a wellestablished and efficient therapeutic option. They improve the clinical condition and the quality of patients' lives. In addition, infusions of immunoglobulin are safe and well tolerated (Table II) . The National Health Fund (Narodowy Fundusz Zdrowia -NFZ) has approved only those indications for immunoglobulin that are registered. These criteria are complied with by only a few childhood rheumatic dis orders (mainly KD). The majority of recommendations mentioned above are not accepted by NFZ. It seems to be very significant to establish clear methods of treat ment for JIA, JDM and JLED. Recommendations for IVIG transfusions in pediatric rheumatology should be widely discussed and updated on the national and global stage. 
